PubRank

Zhuyan Guo

Author PubWeight™ 25.28‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. J Med Chem 2006 2.09
2 Loss of adenomatous polyposis coli gene function disrupts thymic development. Nat Immunol 2005 1.66
3 Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral Res 2007 1.55
4 A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis. Cancer Res 2009 1.48
5 c-Myc mediates pre-TCR-induced proliferation but not developmental progression. Blood 2006 1.39
6 Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization. J Med Chem 2007 1.21
7 Dietary supplementation with white button mushroom enhances natural killer cell activity in C57BL/6 mice. J Nutr 2007 1.09
8 Identification of HCV protease inhibitor resistance mutations by selection pressure-based method. Nucleic Acids Res 2009 1.07
9 Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors. Biochemistry 2006 0.94
10 Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket. Bioorg Med Chem Lett 2008 0.90
11 Beta-catenin/Tcf determines the outcome of thymic selection in response to alphabetaTCR signaling. J Immunol 2009 0.86
12 Discovery of potent sulfonamide P4-capped ketoamide second generation inhibitors of hepatitis C virus NS3 serine protease with favorable pharmacokinetic profiles in preclinical species. Bioorg Med Chem 2010 0.86
13 White button mushroom enhances maturation of bone marrow-derived dendritic cells and their antigen presenting function in mice. J Nutr 2008 0.86
14 Conformation constraint of anilides enabling the discovery of tricyclic lactams as potent MK2 non-ATP competitive inhibitors. Bioorg Med Chem Lett 2013 0.84
15 Toward the back-up of boceprevir (SCH 503034): discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles. J Med Chem 2009 0.83
16 Green tea EGCG suppresses T cell proliferation through impairment of IL-2/IL-2 receptor signaling. Free Radic Biol Med 2009 0.83
17 Evaluation of cancer dependence and druggability of PRP4 kinase using cellular, biochemical, and structural approaches. J Biol Chem 2013 0.81
18 The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitors. Bioorg Med Chem Lett 2009 0.80
19 Expression of multiple artificial microRNAs from a chicken miRNA126-based lentiviral vector. PLoS One 2011 0.79
20 The introduction of P4 substituted 1-methylcyclohexyl groups into Boceprevir: a change in direction in the search for a second generation HCV NS3 protease inhibitor. Bioorg Med Chem Lett 2010 0.78
21 Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations. Antivir Ther 2014 0.78
22 Biaryl substituted hydantoin compounds as TACE inhibitors. Bioorg Med Chem Lett 2010 0.77
23 2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors. Bioorg Med Chem Lett 2011 0.77
24 Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors: Part I--discovery of two binding modes. J Med Chem 2008 0.76
25 Key steps in the structure-based optimization of the hepatitis C virus NS3/4A protease inhibitor SCH503034. J Synchrotron Radiat 2008 0.75
26 Novel TNF-α converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases. Bioorg Med Chem Lett 2010 0.75
27 Structure and activity relationships of tartrate-based TACE inhibitors. Bioorg Med Chem Lett 2010 0.75
28 Towards the second generation of Boceprevir: Dithianes as an alternative P2 substituent for 2,2-dimethyl cycloproyl proline in HCV NS3 protease inhibitors. Bioorg Med Chem Lett 2010 0.75
29 Discovery and SAR of hydantoin TACE inhibitors. Bioorg Med Chem Lett 2010 0.75